HomeCompareCTLT vs SPHD

CTLT vs SPHD: Dividend Comparison 2026

CTLT yields 3.15% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPHD wins by $2.1K in total portfolio value
10 years
CTLT
CTLT
● Live price
3.15%
Share price
$63.48
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$385.93
Full CTLT calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — CTLT vs SPHD

📍 SPHD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTLTSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTLT + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTLT pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTLT
Annual income on $10K today (after 15% tax)
$267.80/yr
After 10yr DRIP, annual income (after tax)
$328.04/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, SPHD beats the other by $157.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTLT + SPHD for your $10,000?

CTLT: 50%SPHD: 50%
100% SPHD50/50100% CTLT
Portfolio after 10yr
$25.5K
Annual income
$478.63/yr
Blended yield
1.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CTLT right now

CTLT
Analyst Ratings
8
Buy
12
Hold
1
Sell
Consensus: Hold
Price Target
$74.25
+17.0% upside vs current
Range: $41.00 — $132.00
Altman Z
1.6
Piotroski
4/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTLT buys
0
SPHD buys
0
No recent congressional trades found for CTLT or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTLTSPHD
Forward yield3.15%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$24.5K$26.5K
Annual income after 10y$385.93$571.32
Total dividends collected$3.5K$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CTLT vs SPHD ($10,000, DRIP)

YearCTLT PortfolioCTLT Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$11,015$315.06$11,133$432.85$118.00SPHD
2$12,110$324.34$12,363$450.36$253.00SPHD
3$13,291$333.26$13,695$467.39$404.00SPHD
4$14,564$341.83$15,138$483.90$574.00SPHD
5$15,933$350.05$16,697$499.88$764.00SPHD
6$17,406$357.91$18,382$515.31$976.00SPHD
7$18,990$365.43$20,198$530.17$1.2KSPHD
8$20,692$372.60$22,157$544.46$1.5KSPHD
9$22,520$379.43$24,266$558.18$1.7KSPHD
10$24,482$385.93$26,536$571.32$2.1KSPHD

CTLT vs SPHD: Complete Analysis 2026

CTLTStock

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Full CTLT Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this CTLT vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTLT vs SCHDCTLT vs JEPICTLT vs OCTLT vs KOCTLT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.